Larimar Therapeutics Shares Decline Following Patient Allergic Reactions in Key Study
Study Overview: Larimar Therapeutics is conducting a long-term open-label study on nomlabofusp for Friedreich’s ataxia, evaluating safety, tolerability, and clinical outcomes, with 65 patients having received doses so far.
Adverse Events and Dosing Changes: Seven participants experienced anaphylaxis, leading to a revised dosing regimen that includes a 5 mg test dose followed by a 25 mg dose, with plans to enroll younger patients aged 2-11 years.
Clinical Improvements: Participants showed median improvements in the modified Friedreich Ataxia Rating Scale and other clinical outcomes compared to a reference population, indicating potential efficacy of the treatment.
Market Reaction: Following the study data release, Larimar's stock (LRMR) fell by 23.75%, trading at $3.89, while the company aims for a marketing application submission for accelerated approval by Q2 2026.
Trade with 70% Backtested Accuracy
Analyst Views on LRMR
About LRMR
About the author
Larimar to Present at 44th J.P. Morgan Healthcare Conference on January 14, 2026
- Investor Meeting Participation: Larimar Therapeutics will participate in 1x1 investor meetings at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in treatments for complex rare diseases, which is expected to attract potential investor interest.
- Product Development Progress: The company's lead compound, nomlabofusp, is under development as a treatment for Friedreich's ataxia, and this innovation could open new market opportunities, enhancing its competitive position in the biotechnology sector.
- Webcast Arrangement: The presentation is scheduled from 9:00 to 9:40 AM PST, and investors can join via the provided webcast link, with a replay available for 30 days on the company’s website, thereby improving engagement with investors.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design additional fusion proteins targeting more rare diseases, demonstrating the company's long-term growth potential and ongoing commitment to innovation in the biotechnology field.
Three Health Care Stocks Poised for Significant Gains This December
Oversold Stocks Opportunity: The health care sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.
Larimar Therapeutics Inc: The company reported a wider-than-expected quarterly loss, with its stock falling 20% over the past month and an RSI of 29.9, closing at $3.12.
Perrigo Company PLC: Perrigo's mixed financial results led to a 34% stock decline in the past month, with an RSI of 29.9, closing at $13.61, despite gaining market share in several categories.
ORIC Pharmaceuticals Inc: After a recent coverage initiation with an Outperform rating, ORIC's stock fell 16% over the past month, with an RSI of 29.6, closing at $10.65.
LRMR Investors Can Participate in Larimar Therapeutics, Inc. Fraud Investigation Led by Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating claims against Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information.
Study Results and Impact: Larimar reported "positive" data from a study on Nomlabofusp for Friedreich's Ataxia but revealed that seven participants experienced severe allergic reactions, leading to a significant drop of over 33.6% in the company's stock price.
Shareholder Rights: The firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations to discuss their rights.
Law Firm's Focus: The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, emphasizing its commitment to shareholder rights litigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Larimar Therapeutics, Inc. and its officers or directors, urging affected investors to reach out for assistance.
Study Data Release: On September 29, 2025, Larimar released data from a study on Nomlabofusp for Friedreich's Ataxia, which, despite being labeled "positive," revealed severe allergic reactions in seven participants.
Stock Price Impact: Following the announcement of the study data, Larimar's stock price dropped significantly by 33.66%, closing at $3.38 per share.
Pomerantz LLP Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial damages awards for class members.
Larimar Therapeutics, Inc. Under Investigation for Securities Fraud - Reach Out to DJS Law Group to Understand Your Rights – LRMR
Investigation Announcement: DJS Law Group is investigating Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.
Study Results and Impact: Following the release of data from a study on a treatment for Friedreich's Ataxia, which was presented positively despite severe allergic reactions in participants, Larimar's shares dropped by 33.66%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Larimar Therapeutics, Inc. and its officers/directors, urging affected investors to contact them.
Stock Price Impact: Following the release of data from a study on Nomlabofusp, which included reports of severe allergic reactions, Larimar's stock price dropped by 33.66%, closing at $3.38 per share.
Larimar to Present at 44th J.P. Morgan Healthcare Conference on January 14, 2026
- Investor Meeting Participation: Larimar Therapeutics will participate in 1x1 investor meetings at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in treatments for complex rare diseases, which is expected to attract potential investor interest.
- Product Development Progress: The company's lead compound, nomlabofusp, is under development as a treatment for Friedreich's ataxia, and this innovation could open new market opportunities, enhancing its competitive position in the biotechnology sector.
- Webcast Arrangement: The presentation is scheduled from 9:00 to 9:40 AM PST, and investors can join via the provided webcast link, with a replay available for 30 days on the company’s website, thereby improving engagement with investors.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design additional fusion proteins targeting more rare diseases, demonstrating the company's long-term growth potential and ongoing commitment to innovation in the biotechnology field.
Three Health Care Stocks Poised for Significant Gains This December
Oversold Stocks Opportunity: The health care sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.
Larimar Therapeutics Inc: The company reported a wider-than-expected quarterly loss, with its stock falling 20% over the past month and an RSI of 29.9, closing at $3.12.
Perrigo Company PLC: Perrigo's mixed financial results led to a 34% stock decline in the past month, with an RSI of 29.9, closing at $13.61, despite gaining market share in several categories.
ORIC Pharmaceuticals Inc: After a recent coverage initiation with an Outperform rating, ORIC's stock fell 16% over the past month, with an RSI of 29.6, closing at $10.65.
LRMR Investors Can Participate in Larimar Therapeutics, Inc. Fraud Investigation Led by Schall Law Firm
Investigation Announcement: The Schall Law Firm is investigating claims against Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information.
Study Results and Impact: Larimar reported "positive" data from a study on Nomlabofusp for Friedreich's Ataxia but revealed that seven participants experienced severe allergic reactions, leading to a significant drop of over 33.6% in the company's stock price.
Shareholder Rights: The firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations to discuss their rights.
Law Firm's Focus: The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, emphasizing its commitment to shareholder rights litigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Larimar Therapeutics, Inc. and its officers or directors, urging affected investors to reach out for assistance.
Study Data Release: On September 29, 2025, Larimar released data from a study on Nomlabofusp for Friedreich's Ataxia, which, despite being labeled "positive," revealed severe allergic reactions in seven participants.
Stock Price Impact: Following the announcement of the study data, Larimar's stock price dropped significantly by 33.66%, closing at $3.38 per share.
Pomerantz LLP Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial damages awards for class members.
Larimar Therapeutics, Inc. Under Investigation for Securities Fraud - Reach Out to DJS Law Group to Understand Your Rights – LRMR
Investigation Announcement: DJS Law Group is investigating Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors.
Study Results and Impact: Following the release of data from a study on a treatment for Friedreich's Ataxia, which was presented positively despite severe allergic reactions in participants, Larimar's shares dropped by 33.66%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Larimar Therapeutics, Inc. and its officers/directors, urging affected investors to contact them.
Stock Price Impact: Following the release of data from a study on Nomlabofusp, which included reports of severe allergic reactions, Larimar's stock price dropped by 33.66%, closing at $3.38 per share.
